ADCGEN

Novel cancer therapeutic drugs

At ADCGEN, we lead the charge in cancer research through cutting-edge innovation and a commitment to discovering novel therapeutic targets. Powered by our proprietary AI-driven platform, we accelerate the development of more effective treatments—delivering hope to patients, faster.

Driving innovation in breakthrough oncology treatments.

Our deep expertise in oncology and artificial intelligence empowers us to analyze vast multimodal datasets with advanced AI algorithms. This capability enables us to uncover novel therapeutic targets, identify lead compounds, elucidate mechanisms of action, and explore synergistic drug combinations. Our platform also drives the development of next-generation antibody-drug conjugates (ADCs), advancing the precision and effectiveness of cancer treatment.

Our R&D Pipeline

At CancerAppy, we harness the power of AI-driven drug discovery to develop groundbreaking cancer therapies, including next-generation antibody-drug conjugates (ADCs). From target identification to preclinical development, our streamlined pipeline accelerates the journey of innovative treatments toward patients in need.

News

Latest news about ADCGEN

ADCGEN: Using AI to Advance Cancer Research

Artificial Intelligence, Big Data, Cancer Reseach

Since 2019, Cancerappy has been harnessing the power of artificial intelligence to transform cancer research, from improving detection and diagnosis...

Integrating artificial intelligence in drug discovery and early drug development

Artificial Intelligence, Cancer Reseach, Publications

Cancerappy Participates in New Scientific Publication on AI in Drug Discovery We’re proud to announce that Cancerappy has contributed to a recently...

Liposomal Formulation of the CDK9 PROTAC THAL-SNS-032 Enhances the Antitumor activity in Breast Cancer

Artificial Intelligence, PROTACs, Publications, SCIENCE

Thrilled to announce our latest work in Biomedicine & Pharmacotherapy (July 12, 2025): “Liposomal formulation of the CDK9 PROTAC THAL‑SNS‑032...